Patients were randomized to tolvaptan 30 mg/day compared with placebo in addition to standard medical therapy for a minimum of 60 days. Jennifer E. Ho, MD, Cardiology Fellow, University of ...
Oral administration of the vasopressin V2-receptor antagonist tolvaptan is safe and effective for the treatment of chronic hyponatremia in the long term, according to the results of the SALTWATER ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback